Atrial Fibrillation — UKMLA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Review bleeding risk and drug interaction
The best answer is “Review bleeding risk and drug interaction”. Apixaban exposure and bleeding risk can rise with interacting CYP3A4 and P-glycoprotein inhibitors, and renal deterioration adds further risk. The patient needs urgent clinical assessment, blood count and renal function review, with the interacting antimicrobial and anticoagulant plan reconsidered. Vitamin K reverses warfarin, not apixaban.
Reference: Eliquis 5 mg tablets Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/2878/smpc